SRNE - Sorrento enters exclusive licensing deal with Aardvark for chronic pain treatment

Sorrento Therapeutics ([[SRNE]] +6.3%) and majority owned subsidiary Scilex Holdings company have entered into an exclusive licensing term sheet with Aardvark Therapeutics to acquire its proprietary formulation, ARD-301, for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome in multiple Phase 2 programs planned to be initiated this year.Scilex plans to work with Aardvark to initiate a new Phase 2 trial this year for fibromyalgia.ARD-301 is comprised of a non-opioid, non-addictive therapy option that has been shown to have activity for improving a broad array of fibromyalgia symptoms in prior clinical studies with LDN.Currently, there are only three FDA approved pharmacologic treatments for fibromyalgia.

For further details see:

Sorrento enters exclusive licensing deal with Aardvark for chronic pain treatment